enter passkey to continue
incorrect passkey
Evidence-based pathways, clinical decision support, and specialist integration for physicians bringing the power of genetic testing to every patient who needs it.
The distance between genomic capability and clinical practice is measured in years of unnecessary patient suffering.
The average physician receives fewer than 10 hours of genetics education across four years of medical school. Yet 1 in 10 patients presenting in primary care carries a genetic condition that could be identified through targeted testing.
This gap produces a predictable pattern: patients cycle through 7 or more specialists over 5 to 7 years before receiving a molecular diagnosis. Along the way, they accumulate redundant imaging, empiric therapies, and exploratory procedures — none of which address the underlying cause.
The problem is not a lack of evidence. Exome and genome sequencing deliver diagnostic yields of 15% to 95% depending on the organ system, with an average midpoint of ~53% across strong-evidence indications. The problem is that this evidence has not been translated into actionable clinical workflows that any physician can follow.
OriginalMD exists to close that gap.
CarePathways transform genetic testing from an ad hoc lab order into a structured, evidence-backed clinical workflow with measurable outcomes.
Identify patients whose clinical presentation — unexplained symptoms across multiple systems, family history signals, or treatment resistance — warrants genomic evaluation.
Choose the right test for the clinical question. Gene panels, exome sequencing, or genome sequencing — each matched to indication-specific evidence for diagnostic yield.
Translate molecular findings into clinical action. Pathogenic variants, variants of uncertain significance, and negative results each require distinct clinical follow-through.
A molecular diagnosis changes everything downstream — surveillance protocols, targeted therapies, reproductive counseling, and the elimination of unnecessary workup.
Track diagnostic yield, time-to-diagnosis, management changes, and downstream utilization reduction to demonstrate value and refine pathways.
As variant databases grow and new gene-disease associations emerge, pathways evolve — ensuring clinicians always work from the current evidence base.
Published exome/genome sequencing yield ranges across Tier 1 organ systems
OriginalMD bridges the gap between the clinician at the bedside and the genetics specialist who can guide diagnosis, interpretation, and management.
Structured referral pathways ensure patients reach the right genetics specialist with complete phenotypic information, reducing back-and-forth and accelerating time to evaluation.
Integrated genetic counseling workflows prepare patients and providers before testing, ensuring informed consent, appropriate test selection, and realistic expectation-setting.
Complex genomic results — including variants of uncertain significance — are reviewed collaboratively between ordering clinicians and genetics specialists, with structured frameworks for clinical decision-making.
When a pathogenic variant is identified, cascade testing protocols guide the systematic evaluation of at-risk family members — turning one diagnosis into a family-wide risk stratification strategy.
OriginalMD is a physician-facing node in the SequenceMedicine network — a coordinated ecosystem of specialty-specific genomic medicine platforms, each built on shared evidence and unified clinical pathways.